The Cancer Letter

Inside information on cancer research and drug development

Drugs & Targets

NEXT Oncology expands phase I program with VCS partnership

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

NEXT Oncology and Virginia Cancer Specialists have joined forces, launching NEXT Virginia, a cancer clinic, in September 2021.

This partnership will also help expand VCS’s phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to the VCS Research Institute. 

The expanded phase I program will begin this fall, while the stand-alone NEXT Virginia clinic, adjacent to Virginia Cancer Specialists, is built. 

NEXT Virginia is headed by Alex Spira, co-director of the VCS Research Institute, who is the site’s clinical director and CEO. Spira is also the director of the VCS thoracic and phase I program and a clinical assistant professor at John Hopkins.

NEXT Oncology has relationships with both Texas Oncology and Virginia Cancer Specialists, both of which are practices in the US Oncology Network. The new clinic will be located at 8613 Lee Highway in Fairfax.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Sponsored

Advancing pediatric oncology and survivorship: A research vision at City of Hope

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.
By Saro Armenian
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account